{"id":1013899,"date":"2026-10-27T07:18:11","date_gmt":"2026-10-27T11:18:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-report-third-quarter-2026-financial-results-on-november-3-2026\/"},"modified":"2026-10-27T07:18:11","modified_gmt":"2026-10-27T11:18:11","slug":"arvinas-to-report-third-quarter-2026-financial-results-on-november-3-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-report-third-quarter-2026-financial-results-on-november-3-2026\/","title":{"rendered":"Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026"},"content":{"rendered":"
\n

NEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review third quarter 2026 financial results and provide a corporate update during a live webcast on Tuesday, November 3, 2026 at 8:00 a.m. ET.<\/p>\n

The webcast can be accessed under \u201cEvents and Presentations\u201d on the investor page<\/a> of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com<\/a> following the completion of the event.<\/p>\n

\n About\u00a0Arvina<\/strong>\n <\/p>\n

Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROteolysis TArgeting Chimera (PROTAC) protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body\u2019s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas, with its partner Pfizer, developed the first U.S. Food and Drug Administration (FDA)-approved PROTAC, a type of heterobifunctional protein degrader, which has been outlicensed to Rigel Pharmaceuticals, Inc. for exclusive global development, manufacturing, and commercialization.\u00a0<\/p>\n

Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-393, targeting BCL6 for relapsed\/refractory non-Hodgkin Lymphoma; ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle for spinal-bulbar muscular atrophy, also known as Kennedy\u2019s disease; and ARV-6723, targeting HPK1 for advanced solid tumors. Arvinas has also advanced ARV-806, targeting KRAS G12D for solid tumors, in the clinic, and previously announced plans to seek an out-licensing agreement for any additional clinical trials of ARV-806, including dose expansion or combination clinical trials. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit\u202fwww.arvinas.com<\/strong><\/a>\u202fand connect on\u202fLinkedIn<\/strong><\/a>\u202fand\u202f<\/strong>X<\/strong><\/a>.\u00a0<\/p>\n

\n Contacts<\/strong>
\n
\n Investors:<\/strong>
\n
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com<\/a><\/strong><\/p>\n

\n Media:<\/strong>
\n
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review third quarter 2026 financial results and provide a corporate update during a live webcast on Tuesday, November 3, 2026 at 8:00 a.m. ET. The webcast can be accessed under \u201cEvents and Presentations\u201d on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event. About\u00a0Arvina Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROteolysis TArgeting … <\/p>\n

Continue reading “Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1013899","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nArvinas to Report Third Quarter 2026 Financial Results on November 3, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-report-third-quarter-2026-financial-results-on-november-3-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review third quarter 2026 financial results and provide a corporate update during a live webcast on Tuesday, November 3, 2026 at 8:00 a.m. ET. The webcast can be accessed under \u201cEvents and Presentations\u201d on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event. About\u00a0Arvina Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROteolysis TArgeting … Continue reading "Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-report-third-quarter-2026-financial-results-on-november-3-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-27T11:18:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzI3MiM3OTE2NzIzIzIxMjIwNzY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-report-third-quarter-2026-financial-results-on-november-3-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-report-third-quarter-2026-financial-results-on-november-3-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026\",\"datePublished\":\"2026-10-27T11:18:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-report-third-quarter-2026-financial-results-on-november-3-2026\\\/\"},\"wordCount\":330,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-report-third-quarter-2026-financial-results-on-november-3-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MzI3MiM3OTE2NzIzIzIxMjIwNzY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-report-third-quarter-2026-financial-results-on-november-3-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-report-third-quarter-2026-financial-results-on-november-3-2026\\\/\",\"name\":\"Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-report-third-quarter-2026-financial-results-on-november-3-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-report-third-quarter-2026-financial-results-on-november-3-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MzI3MiM3OTE2NzIzIzIxMjIwNzY=\",\"datePublished\":\"2026-10-27T11:18:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-report-third-quarter-2026-financial-results-on-november-3-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-report-third-quarter-2026-financial-results-on-november-3-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-report-third-quarter-2026-financial-results-on-november-3-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MzI3MiM3OTE2NzIzIzIxMjIwNzY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MzI3MiM3OTE2NzIzIzIxMjIwNzY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-to-report-third-quarter-2026-financial-results-on-november-3-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-report-third-quarter-2026-financial-results-on-november-3-2026\/","og_locale":"en_US","og_type":"article","og_title":"Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026 - Market Newsdesk","og_description":"NEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review third quarter 2026 financial results and provide a corporate update during a live webcast on Tuesday, November 3, 2026 at 8:00 a.m. ET. The webcast can be accessed under \u201cEvents and Presentations\u201d on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event. About\u00a0Arvina Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROteolysis TArgeting … Continue reading \"Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-report-third-quarter-2026-financial-results-on-november-3-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-27T11:18:11+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzI3MiM3OTE2NzIzIzIxMjIwNzY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-report-third-quarter-2026-financial-results-on-november-3-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-report-third-quarter-2026-financial-results-on-november-3-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026","datePublished":"2026-10-27T11:18:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-report-third-quarter-2026-financial-results-on-november-3-2026\/"},"wordCount":330,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-report-third-quarter-2026-financial-results-on-november-3-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzI3MiM3OTE2NzIzIzIxMjIwNzY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-report-third-quarter-2026-financial-results-on-november-3-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-report-third-quarter-2026-financial-results-on-november-3-2026\/","name":"Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-report-third-quarter-2026-financial-results-on-november-3-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-report-third-quarter-2026-financial-results-on-november-3-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzI3MiM3OTE2NzIzIzIxMjIwNzY=","datePublished":"2026-10-27T11:18:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-report-third-quarter-2026-financial-results-on-november-3-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-report-third-quarter-2026-financial-results-on-november-3-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-report-third-quarter-2026-financial-results-on-november-3-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzI3MiM3OTE2NzIzIzIxMjIwNzY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzI3MiM3OTE2NzIzIzIxMjIwNzY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-to-report-third-quarter-2026-financial-results-on-november-3-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1013899","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1013899"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1013899\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1013899"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1013899"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1013899"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}